Heterozygous Familial Hypercholesterolemia clinical trials

Explore recruiting heterozygous familial hypercholesterolemia clinical trials.

Recruiting heterozygous familial hypercholesterolemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heterozygous Familial Hypercholesterolemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study 1002-041: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia

Germany, Netherlands, Denmark, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)

Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (6 to less than 12 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-20)

Czechia, Portugal, Netherlands, France, Belgium, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia

Finland, Norway, Spain, Netherlands, Czechia, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

France, Denmark, Hungary, Italy, Netherlands, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Heterozygous Familial Hypercholesterolemia trials by city

Heterozygous Familial Hypercholesterolemia in Toronto Heterozygous Familial Hypercholesterolemia in Vancouver Heterozygous Familial Hypercholesterolemia in Montreal Heterozygous Familial Hypercholesterolemia in Calgary Heterozygous Familial Hypercholesterolemia in Edmonton Heterozygous Familial Hypercholesterolemia in Ottawa Heterozygous Familial Hypercholesterolemia in Winnipeg Heterozygous Familial Hypercholesterolemia in Quebec City Heterozygous Familial Hypercholesterolemia in Hamilton Heterozygous Familial Hypercholesterolemia in Kitchener Heterozygous Familial Hypercholesterolemia in London Heterozygous Familial Hypercholesterolemia in Halifax Heterozygous Familial Hypercholesterolemia in New York Heterozygous Familial Hypercholesterolemia in Los Angeles Heterozygous Familial Hypercholesterolemia in Chicago Heterozygous Familial Hypercholesterolemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease